Camurus AB (publ)
SSE:CAMX.ST
440 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Camurus AB (publ) |
Symbool | CAMX.ST |
Munteenheid | SEK |
Prijs | 440 |
Beurswaarde | 25,354,384,000 |
Dividendpercentage | 0% |
52-weken bereik | 197.6 - 599.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Fredrik Tiberg |
Website | https://www.camurus.com |
An error occurred while fetching data.
Over Camurus AB (publ)
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)